AstraZeneca (LSE:AZN) Wins FDA Priority Review For IMFINZI In Bladder Cancer

RegulatoryIMFINZIPositive

AI Analysis

Summary

AstraZeneca received FDA Priority Review designation for IMFINZI in bladder cancer treatment. Priority Review expedites the regulatory review process, typically reducing review timelines.

Outcome Details

Priority Review awarded

Importance:6/10

Sentiment:

0.70

FDApriority_reviewoncologybladder_cancer

Related Companies

$AZN

Read the original article

Published by yahoo_finance on September 30, 2026 12:12 PM

Read Original